CONTACT:
Denise J. Herich
Vice President
Hill & Knowlton, for Correlogic Systems, Inc.
202-944-3367
denise.herich@hillandknowlton.com

CORRELOGIC SYSTEMS SIGNS AGREEMENTS WITH NIH, FDA, AND NCI

Company to Expand Early Disease Detection Research
As Published in The Lancet

BETHESDA, MD, April 5, 2002 - Correlogic Systems, Inc. today entered into a licensing arrangement with the National Institutes of Health (NIH) and a research agreement with the Food and Drug Administration (FDA) and the National Cancer Institute (NCI). The company signed an exclusive, worldwide licensing agreement with the NCI for the shared invention of using patterns of protein expression to detect disease as well as other biological states. Through a Cooperative Research and Development Agreement (CRADA) also signed today, the FDA, NCI and Correlogic Systems will continue their joint research in the identification of patterns of protein expression that detect diseases such as cancer.

A study conducted by Correlogic, FDA and NCI was fast-track published in the February 16, 2002 issue of The Lancet. The study revealed that it is possible to detect ovarian cancer, even at its earliest stage, by analyzing patterns of proteins from a small sample of blood. The same process and technology may also be used to discover patterns - or "models" - signaling other cancers and diseases.

LICENSING ARRANGEMENT
The arrangement provides for the commercialization of the intellectual property rights associated with the concept of patterns of molecular expression as a diagnostic tool. The arrangement will allow Correlogic to enter into sub-licensing, joint venture and other agreements with for-profit and non-profit organizations and, importantly, will facilitate the rapid commercialization of the technology and the development of clinical diagnostic tests. Correlogic is committed to moving the technology from the research laboratory into the hands of health care providers as soon as possible.

CRADA
Research conducted under the CRADA aims to further validate and expand the joint research that has begun in examining patterns of protein expression for the early screening and detection of diseases, with the hopes of addressing several unmet medical needs. In addition to early cancer detection, researchers will apply the same technique to the investigation of drug toxicity, drug metabolism, prion diseases and viral agents.

"We are very pleased to extend this groundbreaking work with Dr. Petricoin, Dr. Liotta and their colleagues at the FDA and NCI Clinical Proteomics Program to other cancers and to apply our technology to the early detection of other disease states," said Peter J. Levine, CEO of Correlogic Systems. "The work we have completed thus far has already changed the way the scientific community views proteomics and early disease detection - but that is only the beginning."

On Monday, April 8, Dr. Ben Hitt, Chief Scientist of Correlogic Systems, will participate on a panel at the annual meeting of the American Association of Cancer Research in San Francisco, CA. Dr. Hitt and other panelists will discuss advances in cancer risk assessment.

Correlogic is the developer and owner of the proprietary software, Proteome Quest^®, which is the central pattern discovery technology used by Correlogic, the FDA and NCI in identifying the protein patterns for the diagnosis of disease. The three organizations jointly own the rights to "A Process for Discriminating between Biological States Based on Hidden Patterns from Biological Data" (Patent Pending), the patent application now licensed from NIH that describes the methodology of discovering disease states through the analysis of patterns of protein expression.

Correlogic Systems, Inc. is a Bethesda, MD-based bioinformatics company engaged in the development of bioinformatic tools and processes for proteomic and genomic-based clinical diagnostic systems and new drug discovery. Correlogic is currently in discussions with a number of potential business partners to rapidly develop diagnostic tests and other biotech applications of the technology. (www.correlogic.com)

###